back to Directory

Kymera Therapeutics

Kymera Therapeutics logo

Founded
2017
Patents
56
Clinical Trials
5
Publications
19

Technologies

Protein Degraders Startups

Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. We are advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients.


Posts Mentioning This Company

9 Innovative Life Sciences Companies to Watch in 2024

  
The biotech and pharmaceutical industries are entering 2024 amid a wave of innovation and technological advancement.  The biopharma field is increasingly influenced by the advent of cutting-edge technologies such as artificial intelligence (AI), organ-on-a-chip systems, and gene editing therapies promising more personalized and precise treatments for a variety of conditions.

Protein Degraders Take Industry By Storm

  
Proteins are essential components of living matter — they function as building blocks for cells and tissues, as well as participate in signaling and practically all biochemical activities.  However, each protein operates correctly only for a limited time and is eliminated by molecular machinery after it has reached its “functional …

Tissue Selective E3 Ligase-based Degraders

  
The efficacy and selectivity of protein degrader drugs depend on their affinity to the target protein but also on the type of E3 ubiquitin ligase (E3) that is recruited to trigger proteasomal degradation. The arsenal of E3s that can be hijacked for targeted protein degradation (TPD) is still largely unexplored. Only about 2% …